Recursion
Script error: No such module "Draft topics". Script error: No such module "AfC topic".
Recursion (Nasdaq: RXRX) is a clinical-stage biotechnology company based in Salt Lake City, Utah that is mapping and decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of improving the lives of patients, and industrializing drug discovery.
● Type: Public ● Traded as ○ Nasdaq: RXRX ● Industry: Biotechnology ● Founded: 2013 ● Headquarters Salt Lake City, Utah, U.S. ● Key people ○ Chris Gibson, Co-Founder and CEO ● Revenue: ● Number of employees: 450 ● Website: https://www.recursion.com/
History
Recursion Pharmaceuticals was founded on November 5, 2013 in Salt Lake City, Utah. Co-founder Chris Gibson, a PhD/MD student at the University of Utah under the guidance of Professor Dean Li, PhD, MD, was studying a method of applying machine learning to microscopy images of human cells. Drawing from his research, Gibson and his co-founders, Li and colleague Blake Borgeson, PhD, created the company to evaluate how to use this methodology to quickly and efficiently explore and discover treatments for a range of human diseases.
Within the first 2 years, Recursion closed its Series A round of funding and signed a research agreement with Sanofi Genzyme. In January 2014, the company moved its operations from Li’s lab at the University of Utah to Recursion’s first facility, and later into a 15,000-square-foot space at the University of Utah’s Research Park. After significant growth, in 2018 Recursion moved into its current location, a 100,000-square-foot facility at the Gateway in downtown Salt Lake City. Recursion currently maintains this facility as well as a satellite office within Mila, the Quebec Artificial Intelligence Institute, in Montreal, Canada, and has cited plans to open a major multidisciplinary location in Toronto.
From 2018 to 2020, Recursion identified and licensed several clinical stage drug candidates, including REC-2282 for Neurofibromatosis type 2, REC-3599 for GM2 gangliosidosis and REC-4881 for solid tumors. In 2020, it also acquired a developer of digitally equipped vivariums for preclinical in vivo research called Vium and announced a partnership with global pharmaceutical company Bayer to support its drug pipeline for fibrotic diseases that impact the lungs, heart, and kidneys, among other organs. The same year the company established Altitude Lab, the region’s largest life sciences incubator, in collaboration with the University of Utah’s PIVOT Center, to “build the economic backbone” for the state of Utah’s health care sector by investing in a “new, diverse generation of founders”.
The company listed on the Nasdaq Stock Exchange on April 20, 2021 under the ticker symbol RXRX. Following this Initial Public Offering, Recursion announced its first internally-developed Novel Chemical Entity (NCE) to Investigational New Drug (IND)-enabling studies focused on searching for treatments for Clostridium difficile Colitis, announced its Canadian office expansions, and opened an on-site child care center for its employees with Bright Horizons, a global provider of early education and child care, back-up care, and workplace education services. In November 2021, Recursion signed a $12B partnership deal with Roche and its subsidiary Genentech to advance therapies in key areas of neuroscience and an undisclosed oncology indication.
Technology
Recursion has developed an integrated operating system combining proprietary in-house data generation and advanced computational tools to generate novel insights to initiate or accelerate therapeutic programs. The company uses a proprietary collection of highly relatable, high-dimensional biological and chemical datasets built in their own laboratories and spanning multiple data modalities. Recursion iterates on this approach to create maps of biology that it believes contain more robust and systematic relationships that help them identify one or more targets or hit compounds which may not have been obvious to choose based on public data or our current limited understanding of a disease. This closed-loop system enables Recursion to reimagine the drug discovery funnel, broadening the funnel with potential therapeutic starting points beyond hypothesized and human-biased targets and narrowing the funnel by identifying failures earlier in the research cycle when they are relatively inexpensive.
Pipeline
Recursion’s pipeline programs target diseases spanning several therapeutic areas across rare diseases and oncology. The company selects diseases where they believe the cause of the disease is well-defined, there is high unmet need, there are no approved therapies, or where there are significant shortcomings with existing treatments. Its current pipeline includes candidates ranging from clinical stage trials to early discovery.
Financials
Series A - On September 2, 2016, Recursion raised a total of $15.05 million in Series A funding, led by Lux Capital, with participation from Obvious Ventures, Epic Ventures, Data Collective, AME Cloud Ventures, Felicis Ventures and several individual investors.
Series B - September 25, 2017, Recursion raised $60 million in Series B funding, led by Data Collective (DCVC), with participation from previous investors Lux Capital, Obvious Ventures, Advantage Capital, Felicis, Epic, and AME. New investors included Mubadala, Menlo Ventures, CRV, Two Sigma and several angel investors.
Series C - On February 12, 2019, Recursion closed $121 million in Series C funding with new lead investor Baillie Gifford. New institutional investors included Intermountain Ventures, Regents of the University of Minnesota, Texas Tech University System. Prior institutional investors that participated included Lux Capital, Data Collective, Mubadala Ventures, Two Sigma Ventures, Obvious Ventures, Felicis Ventures, Epic Ventures, Menlo Ventures, AME Cloud Ventures, and CRV, and several angel investors.
Series D - On September 9, 2020, Recursion raised $239 million in Series D funding, which was reported by Endpoints News to be more than any US or European biotech had raised in a round that year in 2020. A significant Series D investor was Bayer, which contributed a $50 million equity investment.
IPO - Recursion closed its initial public offering on the Nasdaq under the ticker RXRX on April 20, 2021, raising $436M .
Partners
Bayer On September 9, 2020, Recursion and Bayer announced the companies had entered into a strategic collaboration agreement to discover and develop treatments for fibrotic diseases of the lung, kidney, heart and more. Their joint announcement stated the partnership would leverage Recursion’s purpose-built artificial intelligence-guided drug discovery platform and Bayer’s small molecule compound library and scientific expertise. This announcement coincided with Recursion’s Series D fundraising in which Leaps by Bayer, the impact investment arm of Bayer AG, led the series with an equity investment of $50 million .
The companies later expanded the collaboration in fibrosis to include Recursion's inferential search capabilities based on its maps of human cellular biology. The technology was said to allow Bayer the ability to accelerate their partnership work in the area of novel fibrotic hypotheses. It is estimated by the companies that each program could generate more than $100 million in commercial milestone payments plus royalties on future sales .
Roche
On December 7, 2021, Roche and its subsidiary, Genentech, committed up to $12 billion to Recursion in exchange for using Recursion’s Operating System (OS) for its therapy discovery in up to 40 programs in areas including neuroscience and a currently undisclosed oncology indication .
Governance
Executive Leadership ● Chris Gibson, Co-founder, Chief Executive Officer and Board Member ● Tina Larson, Chief Operating Officer and President ● Michael Secora, Chief Financial Officer ● Shafique Virani, Chief Corporate Development Officer ● Louisa Daniels, Chief Legal Officer and General Counsel ● Heather Kirkby, Chief People Officer ● Ben Mabey, Chief Technology Officer
Notable Board members/Board of Directors ● Chris Gibson, Co-founder, Chief Executive Officer and Board Member ● Co-Founder Dan Li, PhD, MD ● Co- Founder Blake Borgeson, PhD ● R. Martin Chavez, Chairman ● Terry-Ann Burrell, Board Member ● Zachary Bogue, Board Member ● Zavain Dar, Board Member ● Robert Hershberg, Board Member
Recognition
● Fierce Life Sciences Innovation Awards (Finalist, 2022) ● Scrip Awards 2022 l Pharma Intelligence (Finalist, 2022) ● Utah Business 2022 Women of The Year (Winner, Tina Marriott, 2022) ● ISS ESG Prime Rating (Winner, 2022) ● Forbes: America’s Best Startup Employers (Winner, 2022) ● One Utah Summit: Medal for Science and Technology (Winner, Chris Gibson, 2022) ● Women’s Tech Council: Shatter Awards (Winner, 2020, 2021, 2022) ● BioUtah Entrepreneur of the Year (Winner, Chris Gibson, 2020) ● CB Insights AI 100 (Winner, 2020) ● Forbes AI 50: America’s Most Promising AI Companies (Winner, 2020) ● Forbes: America’s Best Startup Employers (Winner, 2020) ● Fast Company Most Innovative Companies 2019 (Winner, 2019) ● Fast Company Most Creative People In Business (Winner, Chris Gibson, 2019) ● Salt Lake Tribune Top Workplaces (Winner, 2018) ● Fierce Innovation Awards: Best Biotech Innovation (Winner, 2016) ● Fierce Innovation Awards: Best in Show - New Product or Service (Winner, 2016)
Research
Recursion has released several open source datasets, including for cells treated with siRNA, a panel of immune perturbations, SARS-CoV-2 virus and a simulation of COVID-19 cytokine storm.
Notable literature and publications associated with Recursion’s research include:
● Circulation, Strategy for Identifying Repurposed Drugs for the Treatment of Cerebral Cavernous Malformation, December 8, 2014 – Founder Chris Gibson's dissertation and the building block of Recursion’s scientific platform, preceding Recursion’s clinical stage treatment for CCM, REC-994. ● Nature Protocol, Cell Painting, a High-Content Image-Based Assay for Morphological Profiling Using Multiplexed Fluorescent Dyes, August 25, 2016 – This protocol describes the design and execution of experiments using Cell Painting, which is a morphological profiling assay that multiplexes six fluorescent dyes, imaged in five channels, to reveal eight broadly relevant cellular components or organelles. ● NF Conference, POPLAR-NF2: A Parallel-Group, Two-Staged, Phase 2/3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of REC-2282 in Participants With Progressive NF2-Mutated Meningiomas, Presented June 18-21, 2022 – Designed to investigate the efficacy and safety of REC-2282, representing a potential new pharmacological treatments for patients with progressive NF2-mutated meningiomas. ● AACR Annual Meeting, Identification and Optimization of Novel Small Molecule Modulators of Immune Checkpoint Resistance with a Unified Representation Space for Genomic and Chemical Perturbations, Presented April 8-12, 2022 – Recursion highlights multiple discovery programs driven by inferred relationships between small molecules and gene knockout with translation from inference to in vivo efficacy. Specifically, prioritizing molecules with activity in STK11-deficient tumors and additional immune checkpoint sensitizers. ● LMRL 2021, Mapping Biology with a Unified Representation Space for Genomic and Chemical Perturbations to Enable Accelerated Drug Discovery ● Proceedings of Machine Learning Research, WILDS: A Benchmark of in-the-Wild Distribution Shifts, Proceedings of the 38th International Conference on Machine Learning, 2021 – Berton Earnshaw and Imran Haque of Recursion contributed a subset of the RxRx1 database for WILDS, a curated benchmark of 10 datasets reflecting a diverse range of distribution shifts that naturally arise in real-world applications, such as shifts across hospitals for tumor identification; across camera traps for wildlife monitoring; and across time and location in satellite imaging and poverty mapping. ● bioRxiv, Functional Immune Mapping with Deep-Learning Enabled Phenomics Applied to Immunomodulatory and COVID-19 Drug Discovery, August 14, 2020 – “Results demonstrate that systems-level modeling and drug discovery is achievable using a single phenomics platform.” ● Identification of Potential Treatments for COVID-19 through Artificial Intelligence-Enabled Phenomic Analysis of Human Cells Infected with SARS-CoV-2 – Research released on possible COVID-19 therapeutics before any trials completed
References[edit]
https://www.sec.gov/Archives/edgar/data/1601830/000119312521089610/d89478ds1.htm https://archive.sltrib.com/article.php?id=2231448&itype=CMSID https://techalaa.medium.com/a-conversation-with-chris-gibson-co-founder-ceo-of-recursion-be30ba77ce08 https://www.businesswire.com/news/home/20161122005228/en/Recursion-Raises-Additional-Funding-Bringing-Total-Series-A-to-15.05M-for-Drug-Discovery https://www.sltrib.com/news/2018/11/01/shopping-center/ https://bioutah.org/wp-content/uploads/2021/07/Recursion-Announces-Multi-Year-Collaboration-with-Mila-for-Tech-Enabled-Drug-Discovery-Mila.pdf https://www.prnewswire.com/news-releases/recursion-announces-its-first-major-multidisciplinary-expansion-in-toronto-to-further-tech-enabled-drug-discovery-301311760.html https://www.businesswire.com/news/home/20190104005077/en/Recursion-Signs-Global-Licensing-Agreement-with-the-Ohio-State-Innovation-Foundation-to-Develop-REC-2282-to-Treat-Neurofibromatosis-Type-2 https://www.sec.gov/Archives/edgar/data/1601830/000119312521089610/d89478ds1.htm https://www.fiercebiotech.com/medtech/recursion-pharma-acquires-digital-vivarium-outfit-vium https://attheu.utah.edu/announcements/altitude-lab-brings-new-generation-of-biotech-to-utah/ https://www.prnewswire.com/news-releases/recursion-announces-first-internally-developed-nce-advanced-to-ind-enabling-studies-to-potentially-treat-clostridium-difficile-colitis-301298163.html https://mila.quebec/en/recursion-announces-multi-year-collaboration-with-mila-for-tech-enabled-drug-discovery/ https://www.prnewswire.com/news-releases/recursion-announces-its-first-major-multidisciplinary-expansion-in-toronto-to-further-tech-enabled-drug-discovery-301311760.html https://www.sltrib.com/news/business/2021/11/02/these-utah-businesses/ https://www.genengnews.com/artificial-intelligence/roche-genentech-recursion-launch-up-to-12b-ai-drug-discovery-effort/ https://www.genengnews.com/gen-edge/the-netflix-of-digital-biologyrecursion-is-reimagining-drug-discovery/ https://www.sec.gov/Archives/edgar/data/1601830/000119312521089610/d89478ds1.htm https://www.recursion.com/pipeline https://www.businesswire.com/news/home/20161003005212/en/Recursion-Pharmaceuticals-Raises-13M-to-Discover-New-Drugs-Using-Artificial-Intelligence https://techcrunch.com/2017/10/03/drug-discovery-startup-recursion-raises-60-million-in-series-b-from-dcvc/?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAHYKpTO4CoR99WJ_loWt7FOwKSowZFSX4C-fdYTQ5XpPLz2pqWrUcHL_YfMgozJBdmgjaEqR6WA4ONxTr4hWSNfiTc-iS1roO4v9dwAlacYdi0-GHWGJX4ovrrPbycjdQ0yqgdOLx1Gkgw2m0snKNrJqmvuk3eSBYESgirs9sZp6 https://www.finsmes.com/2019/07/recursion-pharmaceuticals-raises-121m-in-series-c-financing.html https://endpts.com/recursion-nabs-239m-and-an-up-to-1b-partnership-with-bayer-as-ai-race-heats-up/ https://www.fiercebiotech.com/medtech/recursion-pharma-nets-239m-plus-ai-research-contract-bayer https://www.bloomberg.com/news/articles/2021-04-16/recursion-pharmaceuticals-jumps-in-debut-after-436-million-ipo#xj4y7vzkg https://www.bayer.com/media/en-us/bayer-collaborates-with-recursion-to-strengthen-digital-drug-discovery-and-advance-new-therapies-for-fibrotic-diseases/ https://ir.recursion.com/2021-12-06-Recursion-and-Bayer-Expand-Fibrosis-Collaboration-to-Include-Inferential-Search-Capabilities https://www.genengnews.com/artificial-intelligence/roche-genentech-recursion-launch-up-to-12b-ai-drug-discovery-effort/ https://ir.recursion.com/leadership https://ir.recursion.com/board-of-directors https://github.com/recursionpharma/rxrx-datasets/blob/trunk/rxrx19a/README.md https://www.nature.com/articles/nprot.2016.105?proof=true&draft=collection https://assets.website-files.com/604197abb436036ef8167c1a/62b0863e0dece901d47fa958_NFConference_Recursion_Poster_6_20_22%20(2).jpg https://assets.website-files.com/6207bf4c54331471d9677af8/625dc91a349c87a2fac05b6a_2022_RXRX_ONC_AACR_FINAL.pdf https://www.biorxiv.org/content/10.1101/2020.08.02.233064v1
This article "Recursion" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Recursion. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
|
This page exists already on Wikipedia. |
